FY2025 · ended Dec 31, 2025 · Revenue $38.73M, -17.5% YoY · Filed Mar 30, 2026
Interpace Biosciences, Inc. (IDXG) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $38.7 million and net income of $24.6 million. Free cash flow was $5.5 million. As of Jun 30, 2026 it held $2.7 million in cash and investments and $974,000 in total debt.
Revenue (TTM)
$36.14M
-20.5% vs year-ago TTM
Net income (TTM)
$24.45M
+435.6% vs year-ago TTM
Operating cash flow (TTM)
$4.46M
-11.8% vs year-ago TTM
Free cash flow (TTM)
$4.10M
-2.4% vs year-ago TTM
EPS (TTM)
$0.89
+432.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
27.70M
+0.0% vs prior year
Net cash
$1.71M
as of Jun 30, 2026
Operating margin
11.5%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- IDXG (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Parsippany, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1054102
- Former names
- Interpace Diagnostics Group, Inc. (until Nov 1, 2019); PDI INC (until Dec 22, 2015); PROFESSIONAL DETAILING INC (until Nov 13, 2002)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $38.7M | $46.9M | $40.0M | $31.8M | $33.1M |
| Operating income | $4.1M | $8.1M | $4.0M | -$3.6M | -$6.3M |
| Net income | $24.6M | $6.7M | $2.0M | -$22.0M | -$14.9M |
| Diluted EPS | $0.89 | $0.40 | $0.45 | — | — |
| Operating cash flow | $5.8M | $4.6M | $3.8M | -$7.7M | -$8.7M |
| Free cash flow | $5.5M | $3.8M | $3.3M | -$8.0M | -$9.1M |
| Total assets | $33.8M | $14.8M | $13.1M | $16.0M | $38.4M |
| Total liabilities | $11.5M | $17.0M | $22.1M | $32.5M | $34.3M |
| Stockholders' equity | $22.4M | -$2.2M | -$55.5M | -$58.1M | -$42.4M |
| Cash and investments | $2.5M | $1.5M | $3.5M | $4.8M | $2.7M |
| Total debt | $1.2M | $1.6M | $1.8M | $4.3M | $1.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 27, 2026 | Aug 27, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Aug 26, 2026 | Aug 20, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 21, 2026 | Aug 20, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
All 1001 Interpace Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.